← Leaderboards
Kathleen Mulligan
University Of California San Francisco
$3,973,439
Attributed
$5,506,106
Total exposure
10
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $893.6K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$5,506,106 · 10
By mechanism
R01$4,104,098 · 2
P30$1,382,552 · 1
M01$19,456 · 7
Top collaborators
- Jean-Marc Schwarz5 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Morris Schambelan$4,926,809
- Thomas Sterling Scanlan$10,376,751
- Barbara A. Koenig$10,743,545
- Marc Kopel Hellerstein$9,825,255
- Seymour Packman$961,450
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHiv InfectionsHuman Therapy EvaluationBody CompositionWeight LossBody WeightAids TherapyBioenergeticsCachexiaQuality Of LifeFunctional AbilityNutrition Related TagDrug Screening /EvaluationAndrogen AnalogOutcomes ResearchAidsAntiaids AgentMetabolicFatty Acid Glycerol EstersMetabolic Abnormality AssessmentKineticsMetabolismDiet
Grant awards (41)
Core A: Human Metabolism$275,265
P30 · FY2019 · DK · contact PI
Core A: Human Metabolism$275,265
P30 · FY2018 · DK · contact PI
Lipogenesis, lipoprotein flux & CVD risk: role of meal composition & frequency$616,825
R01 · FY2017 · HL
Core A: Human Metabolism$276,752
P30 · FY2017 · DK · contact PI
Lipogenesis, lipoprotein flux & CVD risk: role of meal composition & frequency$613,174
R01 · FY2016 · HL
Core A: Human Metabolism$277,443
P30 · FY2016 · DK · contact PI
Lipogenesis, lipoprotein flux & CVD risk: role of meal composition & frequency$607,272
R01 · FY2015 · HL
Core A: Human Metabolism$277,827
P30 · FY2015 · DK · contact PI
Lipogenesis, lipoprotein flux & CVD risk: role of meal composition & frequency$604,426
R01 · FY2014 · HL
Lipogenesis, lipoprotein flux & CVD risk: role of meal composition & frequency$623,638
R01 · FY2013 · HL
METABOLIC EFFECTS OF PROTEASE INHIBITORS IN HIV DISEASE$1,518
M01 · FY2005 · RR
VIRAL BURDEN, ALTERED METABOLISM, AND HIV WASTING$1,517
M01 · FY2005 · RR
METABOLIC EFFECTS OF PROTEASE INHIBITORS IN HIV DISEASE$13,092
M01 · FY2004 · RR
Viral burden, altered metabolism, and HIV wasting$1,637
M01 · FY2004 · RR
METABOLIC EFFECTS OF PROTEASE INHIBITORS IN HIV DISEASE$257,477
R01 · FY2002 · DK
PROTEIN SUPPLEMENT FOR HIV+ SUBJECTS W/ WEIGHT LOSS$0
M01 · FY2002 · RR
NANDROLONE IN HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2002 · RR
NANDROLONE IN HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2002 · RR
INHIBITION OF CYTOKINE PRODUCTION/VIRAL REPLICATION ON BODY COMPOSITION$0
M01 · FY2002 · RR
INHIBITION OF CYTOKINE PRODUCTION/VIRAL REPLICATION ON BODY COMPOSITION$0
M01 · FY2002 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2002 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2002 · RR
PROTEIN SUPPLEMENT FOR HIV+ SUBJECTS W/ WEIGHT LOSS$0
M01 · FY2002 · RR
METABOLIC EFFECTS OF PROTEASE INHIBITORS IN HIV DISEASE$379,416
R01 · FY2001 · DK
PROTEIN SUPPLEMENT FOR HIV+ SUBJECTS W/ WEIGHT LOSS$0
M01 · FY2001 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2001 · RR
INHIBITION OF CYTOKINE PRODUCTION/VIRAL REPLICATION ON BODY COMPOSITION$0
M01 · FY2001 · RR
NANDROLONE IN HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2001 · RR
METABOLIC EFFECTS OF PROTEASE INHIBITORS IN HIV DISEASE$401,870
R01 · FY2000 · DK
NANDROLONE IN HIV ASSOCIATED WEIGHT LOSS$564
M01 · FY2000 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$564
M01 · FY2000 · RR
INHIBITION OF CYTOKINE PRODUCTION/VIRAL REPLICATION ON BODY COMPOSITION$564
M01 · FY2000 · RR
PROTEIN SUPPLEMENT FOR HIV+ SUBJECTS W/ WEIGHT LOSS$0
M01 · FY2000 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2000 · RR
NANDROLONE IN HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2000 · RR
NANDROLONE IN HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2000 · RR
ACTG 329: NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2000 · RR
INHIBITION OF CYTOKINE PRODUCTION/VIRAL REPLICATION ON BODY COMPOSITION$0
M01 · FY2000 · RR
INHIBITION OF CYTOKINE PRODUCTION/VIRAL REPLICATION ON BODY COMPOSITION$0
M01 · FY2000 · RR
PROTEIN SUPPLEMENT FOR HIV+ SUBJECTS W/ WEIGHT LOSS$0
M01 · FY2000 · RR
PROTEIN SUPPLEMENT FOR HIV+ SUBJECTS W/ WEIGHT LOSS$0
M01 · FY2000 · RR